Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling
Mar 04, 04:30 PM
Share
Subscribe
In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in its Irish facility to scale global oral GLP-1 production.